MOTOR EFFECTS OF PDE10A INHIBITORS IN PRIMATES

PDE10A 抑制剂对灵长类动物的运动影响

基本信息

  • 批准号:
    7958261
  • 负责人:
  • 金额:
    $ 5.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-01 至 2010-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The cyclic nucleotide phosphodiesterase 10A (PD10A) is highly expressed in the striatum where it participates in signaling mechanisms related to cognitive and motor function. In recent years, selective PDE10A inhibitors have been synthesized, and preclinical tests of these agents have shown significant therapeutic potential for schizophrenia. At this time, the effects of these drugs on other realms of behavior are less clear. As with other antipsychotic drugs, it will be particularly important to evaluate the motor effects of PDE10A inhibitors. These effects are not fully characterized, and we will study them in non-human primates. Knowing such motor effects would not only help us predict potential side effects of the clinical use of these drugs in schizophrenia, but may also lead us to discover alternative applications for PDE10A inhibitors. As indicated by recent physiology data, PDE10A may be expressed predominantly in certain subpopulations of striatal neurons that could then be selectively targeted by PDE10A inhibitors. Imbalances between the activities of neuronal subpopulations in the striatum are at the core of the pathophysiology of movement disorders such as Parkinson's disease. It is therefore conceivable that PDE10A inhibitors may show efficacy against parkinsonian symptoms. In this project, we will characterize the motor effects of TP-10, a selective PDE10A inhibitor, in primates. This is a newly activated project.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STELLA PAPPA其他文献

STELLA PAPPA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STELLA PAPPA', 18)}}的其他基金

NMDA-R2B ANTAGONISTS FOR THE THERAPY OF PARKINSON?S DISEASE
用于治疗帕金森病的 NMDA-R2B 拮抗剂
  • 批准号:
    7958259
  • 财政年份:
    2009
  • 资助金额:
    $ 5.48万
  • 项目类别:
REGULATION OF MOTOR FUNCTION IN PARKINSON'S DISEASE
帕金森病运动功能的调节
  • 批准号:
    7958152
  • 财政年份:
    2009
  • 资助金额:
    $ 5.48万
  • 项目类别:
NMDA RECEPTOR AS THERAPEUTIC TARGET FOR PARKINSON?S DISEASE
NMDA 受体作为帕金森病的治疗靶点
  • 批准号:
    7958260
  • 财政年份:
    2009
  • 资助金额:
    $ 5.48万
  • 项目类别:
REGULATION OF MOTOR FUNCTION IN PARKINSON'S DISEASE
帕金森病运动功能的调节
  • 批准号:
    7715724
  • 财政年份:
    2008
  • 资助金额:
    $ 5.48万
  • 项目类别:
REGULATION OF MOTOR FUNCTION IN PARKINSON'S DISEASE
帕金森病运动功能的调节
  • 批准号:
    7562574
  • 财政年份:
    2007
  • 资助金额:
    $ 5.48万
  • 项目类别:
EFFECTS OF CE IN THE MPTP PRIMATE MODEL OF PARKINSON'S DISEASE
CE 对帕金森病 MPTP 灵长类动物模型的影响
  • 批准号:
    7562575
  • 财政年份:
    2007
  • 资助金额:
    $ 5.48万
  • 项目类别:
REGULATION OF MOTOR FUNCTION IN PARKINSON'S DISEASE
帕金森病运动功能的调节
  • 批准号:
    7349230
  • 财政年份:
    2006
  • 资助金额:
    $ 5.48万
  • 项目类别:
EFFECTS OF CE IN THE MPTP PRIMATE MODEL OF PARKINSON'S DISEASE
CE 对帕金森病 MPTP 灵长类动物模型的影响
  • 批准号:
    7349231
  • 财政年份:
    2006
  • 资助金额:
    $ 5.48万
  • 项目类别:
EFFECTS OF CE IN THE MPTP PRIMATE MODEL OF PARKINSON'S DISEASE
CE 对帕金森病 MPTP 灵长类动物模型的影响
  • 批准号:
    7165984
  • 财政年份:
    2005
  • 资助金额:
    $ 5.48万
  • 项目类别:
REGULATION OF MOTOR FUNCTION IN PARKINSON'S DISEASE
帕金森病运动功能的调节
  • 批准号:
    7165983
  • 财政年份:
    2005
  • 资助金额:
    $ 5.48万
  • 项目类别:

相似海外基金

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10661090
  • 财政年份:
    2022
  • 资助金额:
    $ 5.48万
  • 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10501196
  • 财政年份:
    2022
  • 资助金额:
    $ 5.48万
  • 项目类别:
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
使用非典型抗精神病药物治疗的患者诱导代谢综合征的可能作用机制
  • 批准号:
    22590157
  • 财政年份:
    2010
  • 资助金额:
    $ 5.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The use of atypical antipsychotic agents and the risk of breast cancer
非典型抗精神病药物的使用和乳腺癌的风险
  • 批准号:
    192724
  • 财政年份:
    2009
  • 资助金额:
    $ 5.48万
  • 项目类别:
    Operating Grants
Indolobenzox- and Thiazepines as Atypical Antipsychotic Agents
吲哚苯氧和硫氮卓类药物作为非典型抗精神病药
  • 批准号:
    7539253
  • 财政年份:
    2008
  • 资助金额:
    $ 5.48万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7676049
  • 财政年份:
    2007
  • 资助金额:
    $ 5.48万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7626881
  • 财政年份:
    2007
  • 资助金额:
    $ 5.48万
  • 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
  • 批准号:
    7333930
  • 财政年份:
    2007
  • 资助金额:
    $ 5.48万
  • 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
  • 批准号:
    7034693
  • 财政年份:
    2006
  • 资助金额:
    $ 5.48万
  • 项目类别:
Muscarinic receptor activators as novel antipsychotic agents
毒蕈碱受体激活剂作为新型抗精神病药
  • 批准号:
    7163800
  • 财政年份:
    2006
  • 资助金额:
    $ 5.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了